Compare Novartis AG (NVS) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs TeraWulf Inc — how do they compare? Novartis AG trades at $139.3 (market cap $262.64B), while TeraWulf Inc trades at $17.17 (market cap $8.91B). The key difference: Novartis AG is far larger — about 29.5× TeraWulf Inc's market cap, and Novartis AG pays a 3.44% dividend while TeraWulf Inc pays none. Which is the better fit depends on your goals.
| NVS | WULF | |
|---|---|---|
Market Cap | $262.64B | $8.91B |
Sector | Health | Technology |
52-Week High | $168.62 | $28.98 |
52-Week Low | $121.80 | $10.49 |
Enterprise Value | $303.97B | $11.53B |
Dividend Yield | 3.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
WULF trades at $17.86, up 8.18% today, amid a bullish technical signal despite mixed moving averages. The company reported a net loss of $661.42M in 2025 with a negative net margin of -1,179.94%, though revenue was $168.46M. Recent news highlights its pivot to AI data centers, including a Kentucky power agreement approval (GlobeNewsWire, 2026-08-24).
Analyst consensus is strongly bullish with a $35.94 price target, but high valuation ratios and persistent losses pose risks. Investment opportunity hinges on successful execution of AI infrastructure expansion, while risks include cash burn and competitive pressures in the data center space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
